4//SEC Filing
SCHLEIFER LEONARD S 4
Accession 0001104659-24-071247
CIK 0000872589other
Filed
Jun 12, 8:00 PM ET
Accepted
Jun 13, 4:01 PM ET
Size
21.4 KB
Accession
0001104659-24-071247
Insider Transaction Report
Form 4
SCHLEIFER LEONARD S
DirectorCEO and President10% Owner
Transactions
- Sale
Common Stock
2024-06-11$1015.28/sh−7,321$7,432,865→ 56,877 total(indirect: By Trust) - Sale
Common Stock
2024-06-11$1016.04/sh−1,743$1,770,958→ 55,134 total(indirect: By Trust) - Sale
Common Stock
2024-06-12$1015.30/sh−14,879$15,106,649→ 40,255 total(indirect: By Trust) - Sale
Common Stock
2024-06-12$1016.62/sh−270$274,487→ 39,985 total(indirect: By Trust) - Conversion
Common Stock
2024-06-12+1,000→ 1,000 total(indirect: By Trust) - Sale
Common Stock
2024-06-12$1025.27/sh−1,000$1,025,270→ 0 total(indirect: By Trust) - Conversion
Class A Stock
2024-06-12−1,000→ 14,775 total(indirect: By Trust)Exercise: $0.00→ Common Stock (1,000 underlying)
Holdings
- 157,552(indirect: 2023 GRAT)
Common Stock
- 5,932(indirect: By 401(k))
Common Stock
- 466,877
Common Stock
- 1,710,790
Class A Stock
Exercise: $0.00→ Common Stock (1,710,790 underlying)
Footnotes (8)
- [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 5, 2024.
- [F2]Represents volume-weighted average price of sales of 7,321 shares of common stock of Regeneron Pharmaceuticals, Inc. (the "Company") on June 11, 2024 at prices ranging from $1,015.00 to $1,015.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price.
- [F3]Represents volume-weighted average price of sales of 1,743 shares of Company stock on June 11, 2024 at prices ranging from $1,016.04 to $1,016.10. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 11, 2024 at each separate price.
- [F4]Represents volume-weighted average price of sales of 14,879 shares of Company stock on June 12, 2024 at prices ranging from $1,015.00 to $1,015.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price.
- [F5]Represents volume-weighted average price of sales of 270 shares of Company stock on June 12, 2024 at prices ranging from $1,016.10 to $1,016.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price.
- [F6]Represents volume-weighted average price of sales of 1,000 shares of Company stock on June 12, 2024 at prices ranging from $1,025.00 to $1,025.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 12, 2024 at each separate price.
- [F7]Class A Stock of the Company converts to common stock of the Company on a one-to-one basis upon certain events or upon election of the shareholder.
- [F8]These shares of Class A Stock are presently convertible and such conversion feature does not expire.
Documents
Issuer
REGENERON PHARMACEUTICALS, INC.
CIK 0000872589
Entity typeother
Related Parties
1- filerCIK 0001218629
Filing Metadata
- Form type
- 4
- Filed
- Jun 12, 8:00 PM ET
- Accepted
- Jun 13, 4:01 PM ET
- Size
- 21.4 KB